Updates are available Correction dated 2022-06-27
Click to view Correction: https://doi.org/10.1038/s41592-022-01561-9
-
Authors
Tak, Y. Esther
Horng, Joy E.
Perry, Nicholas T. http://orcid.org/0000-0002-1702-4178
Schultz, Hayley T.
Iyer, Sowmya
Yao, Qiuming
Zou, Luli S.
Aryee, Martin J. http://orcid.org/0000-0002-6848-1344
Pinello, Luca
Joung, J. Keith http://orcid.org/0000-0001-5630-5645
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM118158)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA211707, R01 CA204954)
St. Jude Children’s Research Hospital
Massachusetts General Hospital
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R00 HG008399, R35 HG010717)
- License Information
-
More Information
Article History
Received: 20 October 2020
Accepted: 28 June 2021
First Online: 5 August 2021
Change Date: 27 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41592-022-01561-9
Competing interests
: J.K.J. has financial interests in Beam Therapeutics, Chroma Medicine (formerly YKY, Inc.), Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, SeQure Dx, Transposagen Biopharmaceuticals and Verve Therapeutics (formerly Endcadia). L.P. has financial interests in Excelsior Genomics, Edilytics and SeQure Dx. M.J.A. has financial interests in Excelsior Genomics and SeQure Dx. The interests of J.K.J., L.P. and M.J.A. were reviewed and are managed by MGH and Partners HealthCare in accordance with their conflict-of-interest policies. S.I. is an employee of Verve Therapeutics. Y.E.T. and J.K.J. are inventors on patent applications that cover epigenetic editing technologies. All other authors have no competing interests.
